ARCHIVES

FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI

This article is from The Cancer Letter archive.

Vol. 03 No. 15 | April 15, 1977

Download PDF Visit The Full Archive

Related Articles

NCI FY94 Budget By Mechanism Under House, Senate Mark

September 24, 1993

Bush Signs Bill To Increase Blood Cancer Research.

May 17, 2002

FDA Approves Xeloda For Breast Cancer After Failure Of Anthracycline Treatment.

September 28, 2001

NCI’s Share Of Gramm-Rudman Cuts For FY 1986 Is $54 Million; Staff Ponders How To Absorb It

January 24, 1986

NCAB Gives Okay To Comp Center Guidelines

December 7, 1979

Modeling Will Be Used For Other Populations

November 26, 2010